Rallybio Corp (RLYB)
About Rallybio Corp
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.
This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.
Financial summary
- Revenue FY2025
- $858.0K
- Net income
- -$9.0M
- Total assets
- $62.3M
- Market cap
- $86.6M
- Operating margin
- -3853.6%
- Net margin
- -1046.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $858.0K
- Operating expenses
- $33.9M
- Operating income
- -$33.1M
- Income tax
- $0
- Net income
- -$9.0M
- EPS (basic)
- $-1.59
- EPS (diluted)
- $-1.59
Balance sheet
- Total assets
- $62.3M
- Current assets
- $61.3M
- Total liabilities
- $4.3M
- Current liabilities
- $4.2M
- Shareholders’ equity
- $58.0M
Cash flow
- Operating cash flow
- -$29.8M
- Investing cash flow
- $47.3M
- Financing cash flow
- $16.0K
- Net cash flow
- $17.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $86.6M
- EPS (diluted)
- $-1.59
- Shares outstanding
- 5.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 29, 2021
Rallybio Corp (RLYB) Stock Price
- Reported a net loss of $9.0M in FY2025.
- Trading near its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Rallybio Corp.
Write a review
News about Rallybio Corp
News & sentiment via Polygon.io
Rallybio Corp: frequently asked questions
Is Rallybio Corp an American company?
Rallybio Corp is a US-based company headquartered in New Haven, Connecticut, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Rallybio Corp headquartered?
Rallybio Corp is headquartered in New Haven, Connecticut, United States.
Is Rallybio Corp publicly traded?
Yes — Rallybio Corp is a publicly traded company. Its stock trades under the ticker symbol RLYB on the NASDAQ.
What does Rallybio Corp do?
Rallybio Corp is an American Pharmaceuticals company in the Health & Beauty sector.
